Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma

Scandinavian Journal of Urology and Nephrology

Volumn 32, Issue 2, 1998, Pages 111-115

  Almroth, Anna ^a,b   Ljung, Gunilla ^b,c   Eklund, Tore ^a   Nordgren, Hans ^b   Kalafatidis, Dimitrios ^a   Ringqvist, Ivar ^a   Nilsson, Sten ^b  

^a CENTRAL HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^c Malar Hospital   (Sweden)

Author keywords

External beam radiotherapy; Local cure; Prostatic adenocarcinoma; Sextant core biopsies; Transrectal ultrasonography

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; ASPIRATION BIOPSY; BEAM THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; EQUIPMENT; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; RADIATION DOSE; TRANSRECTAL ULTRASONOGRAPHY; TRANSURETHRAL RESECTION;

ADENOCARCINOMA; AGED; BIOPSY; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 0031967539     PISSN: 00365599     EISSN: None     Source Type: Journal    
DOI: 10.1080/003655998750014477     Document Type: Article

References (39)

1. Babaian RJ, Kojima M, Saitih M, Ayala AG. Detection of residual prostate cancer after external radiotherapy. Cancer 1995; 75: 2153-2158.
2. Bagshaw MA, Kaplan ID, Cox RC. Radiation therapy for localized disease. Cancer 1993; 71: 939-952.
3. Cancer Incidence in Sweden 1989, National Board of Health and Welfare The Cancer Registry 1990.
4. Cangh PJ, Richard FJ. Prostate-specific antigen after definitive radiation therapy. Urology 1994; 4: 256-260.
5. Crook JM, Perry GA, Robertson S, Esche BA. Routine prostate biopsies following radiotherapy for prostate cancer; results for 226 patients. Urology 1995; 45: 624-632.
6. Crook J, Robertson S, Collin G, Zaleski V, Esche B. Clinical relevance of trans-rectal ultrasound, biopsy, and serum prostate-specific antigen following external beam radiotherapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1993; 27: 31-37.
7. de la Torre M, Häggman M, Brändstedt S, Busch C. Prostatic intraepithelial neoplasia and invasive carcinoma in total prostatectomy specimens: distribution, volumes and DNA ploidy. Br J Urol 1993; 72: 207-213.
8. Dughan TC, Shipley WU, Young RH, Verhey LJ, Althausen AF, Heney NM, et al. Biopsy after external radiation therapy for adenocarcinoma of the prostate: correlation with original histological grade and current prostate specific antigen level. J Urol 1991; 146: 1313-1316.
9. Freiha FS, Bagshaw MA. Carcinoma of the prostate: results of post-irradiation biopsy. The Prostate 1984; 5: 19-25.
10. 125I implantation. Int J Radiat Oncol Biol Phys 1991; 21: 537-547.
11. Gleason FD, Mellinger GT. The Veterans Administration Cooperative Urological Research Group. Prediction of prognosis for prostatic adenocarcinoina by combined histological grading and clinical staging. J Urol 1974; 111: 58-64.
12. Grayhack JT. The management of clinically localized prostate cancer. National Institutes of Health Consensus Development Conference. J Urol 1987; 138: 1369-1375.
13. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. PSA confirmation of cure at 10 years of T1B, T2, N0, M0. Prostate cancer patients treated in RTOG protocol 7706 with external beam radiation. Int J Radiat Oncol Biol Phys 1994; 30: 289-292.
14. Herr HW, Whitmore Jr WF. Significance of prostatic biopsies after radiation therapy for carcinoma of the prostate. The Prostate 1982; 3: 339-350.
15. ICRU Report 50. Prescribing, recording, and reporting photon beam therapy..
16. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA. Identification of residual cancer in the prostate following radiation therapy: role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 1989; 142: 326-331.
17. Kiesling VJ, McAninch JW, Goebel JL, Agee RE. External beam radiotherapy for adenocarcinoma of the prostate: a clinical follow-up. J Urol 1980; 124: 851-854.
18. Kirk J, Gray WM, Watson ER. Cumulative radiation effect part I: Fractionated treatment regimes. Clin Radiol 1971; 22: 145-155.
19. Kuban DA, El-Madhi AM. Radiotherapy in the treatment of apparently localized prostatic carcinoma. In: Controversies in the management of prostate cancer. CoMed Communications, 1990; part 3: 4.
20. Kuban DA, El-Madhi AM, Schellhammer P. The significance of post-irradiation prostate biopsy with long-term follow-up. Int J Radiat Oncol Biol Phys 1992; 24: 409-414.
21. Leach GE, Cooper JF, Kagan AR, Snyder R, Forsthe A. Radiotherapy for prostatic carcinoma: post-irradiation prostatic biopsy and recurrence patterns with long-term follow-up. J Urol 1982; 128: 505-509.
22. Ljung G. Radiotherapy of prostatic adenocarcinoma with reference to local cure, characterization of residual tumour cells, adverse effects. Comprehensive summaries of Uppsala dissertations from the Faculty of Medicine 630, Acta Universitatis Upsaliensis, Uppsala 1996: 14-16.
23. Ljung G, Norberg M, Hansson H, de la Torre M, Egevad L, Holmberg L, et al. Transrectal ultrasonically guided core biopsies in the assessment of local cure of prostatic cancer after radical external beam radiotherapy. Acta Oncol 1995; 34: 945-952.
24. 125I seeds. J Urol 1979; 121: 306-309.
25. McLoughlin M, Hazra T, Schirmer HK, Scott WW. Telecobalt therapy for prostatic cancer: rationale, results and future considerations. J Urol 1975; 113: 378-379.
26. Mostofi FK. Grading of prostatic carcinoma. Cancer Chem Rep 1975; 59: 111-117.
27. Nachtsheim DA, McAninch , Stutzman RE, Goebel JL. Latent residual tumor following external radiotherapy for prostate adenocarcinoma. J Urol 1978; 120: 312-314.
28. Norberg M, Holmberg L, Magnusson A. Determinants of complications after multiple transrectal core biopsies of the prostate. 1994 Submitted for publication..
29. Norberg M, Häggman M, Andersson T, Busch C, Magnusson A. Evaluation of localised prostate cancer: a comparative study of transrectal ultrasonography versus histopathology. Eur Radiol 1993; 3: 166-173.
30. Prestidge BR, Kaplan I, Cox RS, Bagshaw MA. The clinical significance of a positive postirradiation prostatic biopsy without metastases. Int J Radiol Oncol Biol Phys 1992; 24: 403-408.
31. Ritter MA, Messing EM, Shanahan TG, Potts S, Chapell RJ, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992; 10: 1208-1217.
32. Rhamy RK, Wilson SK, Caldwell WL. Biopsy-proved tumor following definitive irradiation for resectable carcinoma of the prostate. J Urol 1972; 107: 627-630.
33. Scardino PT, Frankel JM, Wheeler TM, Meacham RB, Hoffman GS, Seale C, et al. The prognostic significance of post-irradiation biopsy results in patients with prostatic cancer. J Urol 1986; 135: 510-516.
34. 125Iodine implant or external beam radiation therapy. J Urol 1987; 137: 897-901.
35. Sewell RA, Braren V, Wilson SK, Rhamy RK. Extended biopsy follow-up after full course radiation for resectable prostatic carcinoma. J Urol 1975; 113: 371-373.
36. Stamey TA. Making the most out of six systematic biopsies. Urology 1995; 45: 2-12.
37. Stamey TA, Ferrari MK, Schmid H-P. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993; 150: 1856-1859.
38. Stamey TA, Kabalin JN, Ferrari M. Prostate specific-antigen in the diagnosis and treatment of adenocarcinoma of the prostate III. Radiation treated patients. J Urol 1989; 141: 1084-1087.
39. Zelefsky MJ, Leibel SA, Wallner KE, Whitmore WF, Fuks Z. Significance of normal serum prostate-specific antigen in the follow-up period after definitive radiation therapy for prostate cancer. J Clin Oncol 1995; 13: 459-463.